Description

The pharmaceutical and biotechnology industry is in a state of transition. Reorganization, mergers and acquisitions, consolidation, and portfolio changes are being evaluated in order to maintain growth centers in the face of a myriad of serious challenges. Overall, companies are looking to align with areas of growth opportunity as well as new business strategy and product development paradigms.